Antifungal agents with protein biosynthesis inhibitory activity

Drugs of the Future

Volumn 25, Issue 1, 2000, Pages 63-71

  Ziegelbauer, Karl ^a,b   Spaltmann, Frank ^a,c  

^a BAYER AG   (Germany)

^b BAYER YAKUHIN LTD   (Japan)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 METHYLENECYCLOPENTANECARBOXYLIC ACID; 2 AMINO 5 HYDROXY 4 OXOVALERIC ACID; 2 AMINOCYCLOPENTANECARBOXYLIC ACID; ANTIFUNGAL AGENT; ASPIROCHLORINE; BETA AMINO ACID; GM 160575; GM 191519; GM 193663; GM 211676; GM 222712; GM 237354; GR 135402; PROTEIN INHIBITOR; SORDARIN; SORDARIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; CANDIDA; CANDIDIASIS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MYCOSIS; NONHUMAN; PROTEIN SYNTHESIS; REVIEW; TRANSLATION REGULATION;

EID: 0034051031     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.01.858641     Document Type: Review

References (60)

1. Perfect, J.R. Fungal infections. Curr Opin Infect Dis 1992, 5: 433-6.
2. Walsh, T.J. Invasive fungal infections: Problems and challenges for developing new antifungal compounds. In: Emerging Targets in Antifungal and Antibacterial Chemotherapy. Sutcliffe, J.A., Georgopapadakou, N.H. (Eds.). Chapman and Hall: New York 1992, 349-73.
3. Beck-Sague, C., Jarvis, W.R. Secular trends in the epidemiology of nosocomial fungal infections in the United States 1980-1990. National Nosociomal Infections Surveillance System. J Infect Dis 1993, 167: 1247-51.
4. Wenzel, R.P. Epidemiology of nosocomial Candida infections. Infect Dis Clin Pract 1994, 3: S56-9.
5. Pittet, D., Wenzel, R.P. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995, 155: 1177-84.
6. Pfaller, M.A. Epidemiology of candidiasis. J Hosp Infect 1995, 30: 329-38.
7. Meunier, F., Aoun, M., Bitar, N. Candidemia in immunocompromised patients. Clin Infect Dis Suppl. 1992, 14: S120-5.
8. Como, J.A., Dismukes, W.E. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994, 330: 263-72.
9. Georgopapadakou, N.H., Walsh, T.J. Human mycoses: Drugs and targets for emerging pathogens. Science 1994, 264: 371-3.
10. Odds, F.C. Editorial overview of antifungals. Curr Opin Antiinfect Invest Drugs 1999, 1: 296.
11. Murray, P.R., Kobayashi, G.S., Pfaller, M.A., Rosenthal, K.S. Medical Microbiology. Mosby-Year Book: London 1994.
12. Pain, V.M. Initiation of protein synthesis in eukaryotic cells. Eur J Biochem 1996, 236: 747-71.
13. Dever, T.E. Translation initiation: Adept at adapting. Trends Biochem Sci 1999, 24: 398-403.
14. Moldave, K. Eukaryotic protein synthesis. Ann Rev Biochem 1985, 54: 1109-49.
15. Proud, C.G. Peptide-chain elongation in eukaryotes. Mol Biol Rep 1994, 9: 161-70.
16. Nakamura, Y., Ito, K., Isaksson, L.A. Emerging understanding of translation termination. Cell 1996, 87: 147-50.
17. Kisselev, L.L., Frolova, L.Y. Termination of translation in eukaryotes: New results and new hypotheses. Biochemistry (Mosc) 1999, 64: 8-16.
18. Belfield, G.P., Tuite, M.F. Translation elongation factor 3: A fungus-specific translation factor? Mol Microbiol 1993, 9: 411-8.
19. Chakraburtty, K. Functional interaction of yeast elongation factor 3 with yeast ribosomes. Int J Biochem Cell Biol 1999, 31: 163-73.
20. Konishi, M., Nishio, M., Saitoh, K., Miyaki, T., Oki, T., Kawaguchi, K. Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure. J Antibiot 1989, 42: 1749-55.
21. Oki, T., Hirano, M., Tomatsu, K., Numata, K., Kamei, H. Cispentacin, a new antifungal antibiotic. II. In vitro and in vivo antifungal activities. J Antibiot 1989, 42: 1756-62.
22. Iwamoto, T., Tsujii, E., Ezaki, M. et al. FR109615, a new antifungal antibiotic from Streptomyces setonii: Taxonomy, fermentation, isolation, physico-chemical properties and biological activity. J Antibiot 1990, 43: 1-7.
23. Ohki, H., Inamoto, Y., Kawabata, K., Kamimura, T., Sakane, K. Synthesis and antifungal activity of FR109615 analogs. J Antibiot 1991, 44: 546-9.
24. Kawabata, K., Inamoto, Y., Sakane, K., Iwamoto, T., Hashimoto, S. Synthesis and structure determination of FR109615, a new antifungal antibiotic. J Antibiot 1990, 43: 513-8.
25. Bremm, K., Endermann, R., Kunisch, F. et al. Cyclopentane-and pentene-β-amino acids. EP 571870.
26. Ziegelbauer, K. β-Amino acid BAY 10-8888, a new systemic antifungal. 3rd Int Antifungal Drug Discov Summit (March 26-27, Princeton) 1997.
27. Capobianco, J., Zakula, D.Z., Coen, M.L., Goldman, R.C. Anti-Candida activity of cispentacin: The active transport of amino acid permeases and its possible mechanism of action. Biochem Biophys Res Commun 1993, 190: 1037-44.
28. Ziegelbauer, K., Babczinski, P., Schönfeld, W. Molecular mode of action of the antifungal beta-amino acid BAY 10-8888. Antimicrob Agents Chemother 1998, 42: 2197-205.
29. Jethwaney, D., Hofer, M., Khaware, R.K., Prasad, R. Functional reconstitution of a purified proline permease from Candida albicans: Interaction with the antifungal cispentacin. Microbiology 1997, 143: 397-404.
30. Hartwell, L.H., McLaughlin, C.S. Mutants of yeast with temperature-sensitive isoleucyl-tRNA synthetases. Proc Natl Acad Sci USA 1968, 59: 422-8.
31. Ziegelbauer, K. Decreased accumulation or increased isoleucyl-tRNA synthetase activity confer resistance to the cyclic beta-amino acid BAY 10-8888 in Candida albicans and Candida tropicalis. Antimicrob Agents Chemother 1998, 42: 1581-6.
32. Gargallo, G.V. Sordarins as antifungal compounds. Curr Opin Anti-infect Invest Drugs 1999, 1: 297-305.
33. Kinsman, O.S., Chalk, P.A., Jackson, H.C. et al. Isolation and characterisation of an antifungal antibiotic GR135402 with protein synthesis inhibition. J Antibiot 1998, 51: 41-9.
34. Coval, S.J., Puar, M.S., Phife, D.W., Terracciano, J.S., Patel, M. SCH57404, an antifungal agent possessing the rare sodaricin skeleton and a tricyclic sugar moiety. J Antibiot 1995, 48: 1171-2.
35. Okada, H., Kamiya, S., Shina, Y. et al. BE-31405, a new antifungal antibiotic produced by Penicillium minioluteum. J Antibiot 1998, 51: 1081-6.
36. Daferner, M., Mensch, S., Anke, T., Sterner, O. Hypoxysordarin, a new sordarin derivative from Hypoxylon croceum. Z Naturforsch [C] 1999, 54: 474-80.
37. Hauser, D., Sigg, H.P. Isolation and decomposition of sordarin. Helv Chim Acta 1971, 54: 1178-90.
38. Dominguez, J.M., Kelly, V.A., Kinsman, O.S., Marriott, M.S., De las Heras, F.G., Martin, J.J. Sordarins: A new class of antifungals with selective inhibition of the protein synthesis elongasion cycle in yeasts. Antimicrob Agents Chemother 1998, 42: 2274-8.
39. Herreros, E., Martinez, C.M., Almela, M.J., Marriott, M.S., De las Heras, F.G., Gargallo-Viola, D. Sordarins: In vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrob Agents Chemother 1998, 42: 2863-9.
40. Graybill, J.R., Najvar, L., Fothergill, A., Bocanegra, R., De las Heras, F.G. Activities of sordarins in murine histoplasmosis. Antimicrob Agents Chemother 1999, 43: 1716-8.
41. Cuevas, J.C., Lavandera, J.L., Martos, J.L. Design and synthesis of simplified sordaricin derivatives as inhibitors of fungal protein synthesis. Bioorg Med Chem Lett 1999, 19: 103-8.
42. Tse, B., Balkovec, J.M., Blazey, C.M., Hsu, M.J., Nielsen, J., Schmatz, D. Alkyl side-chain derivatives of sordaricin as potent antifungal agents against yeast. Bioorg Med Chem Lett 1998, 18: 2269-72.
43. Capa, L., Mendoza, A., Lavandera, J.L., De las Heras, F.G., Garcia-Bustos, J.F. Translation elongation factor 2 is part of the target for a new family of antifungals. Antimicrob Agents Chemother 1998, 42: 2694-9.
44. Dominguez, J.M., Martin, J.J. Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans. Antimicrob Agents Chemother 1998, 42: 2279-83.
45. Justice, M.C., Hsu, M.J., Tse, B. et al. Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis. J Biol Chem 1998, 273: 3148-51.
46. Evarsson, A., Brazhnikov, E., Garber, M. et al. Three-dimensional structure of the ribosomal translocase: Elongation factor G from Thermus thermophilus. EMBO J 1994, 13: 3669-77.
47. Czworkowski, J., Wang, J., Steitz, T.A., Moore, P.B. The crystal structure of elongation factor G complexed with GDP, at 2.7 Angstrom resolution. EMBO J 1994, 13: 3661-8.
48. Dominguez, J.M., Gomez-Lorenzo, M.G., Martin, J.J. Sordarin inhibits fungal protein synthesis by blocking translocation differently to fusidic acid. J Biol Chem 1999, 274: 22423-7.
49. Gomez-Lorenzo, M.G., Garcia-Bustos, J.F. Ribosomal P-protein stalk function is targeted by sordarin antifungals. J Biol Chem 1998, 273: 25041-4.
50. Justice, M.C., Ku, T., Hsu, M.J., Carniol, K., Schmatz, D., Nielsen, J. Mutations in ribosomal protein L10e confer resistance to the fungal-specific eukaryotic elongation factor 2 inhibitor sordarin. J Biol Chem 1999, 274: 4869-75.
51. Kato, A., Saeki, T., Suzuki, K., Ando, K., Tamura, G. Oryzachlorine, a new antifungal antibiotic. J Antibiot 1969, 22: 322-6.
52. Berg, D.H., Massing, R.P., Hoehn, M.M., Boeck, L.D., Hamill, R.L. A30641, a new epidithiodiketopiperazine with antifungal activity. J Antibiot 1976, 29: 394-7.
53. Sakata, K., Masago, H., Sakurai, A., Takahashi, N. Isolation of aspirochlorine antibiotic A-30641 posessing a novel dithio diketopiperazine structure from Aspergillus flavus. Tetrahedron Lett 1982, 23: 2095-8.
54. Sakata, K., Kuwatsuka, T., Sakurai, A., Takahashi, N., Tamura, G. Isolation of aspirochlorine (antibiotic A30641) as a true antimicrobial constituent of the antibiotic oryzachlorine from Aspergillus oryzae. Agric Biol Chem 1983, 47: 2673-4.
55. Sakata, K., Maruyama, M., Uzawa, A., Sakurai, A., Lu, H.S.M., Clardy, J. Strucutral revision of aspirochlorine (antibiotic A30641), a novel epi-dithiopiperazine-2,5,indone produced by Aspergillus spp. Tetrahedron Lett 1987, 28: 5607-10.
56. Monti, F., Ripamonti, F., Hawser, S.P., Islam, K. Aspirochlorine: A highly selective and potent inhibitor of fungal protein synthesis. J Antibiot 1999, 52: 311-8.
57. Yamaki, H., Yamaguchi, M., Nishimura, T., Shinoda, T., Yamaguchi, H. Unique mechanism of action of an antifungal antibiotic RI-331. Drugs Exp Clin Res 1988, 14: 467-72.
58. Yamaguchi, M., Yamaki, H., Shinoda, T. et al. The mode of antifungal action of (S)-2-amino-4-oxo-5-hydroxypentanoic acid, RI-331. J Antibiot 1990, 43: 411-6.
59. Yamaki, H., Yamaguchi, M., Tsuruo, T., Yamaguchi, H. Mechanism of action of an antifungal antibiotic, RI-331, (S)-2-amino-4-oxo-5-hydroxypentanoic acid: Kinetics of inactivation of homoserine dehydrogenase from Saccharomyces cerevisiae. J Antibiot 1992, 45: 750-5.
60. Yamaki, H., Yamaguchi, M., Imamura, H. et al. The mechanism of antifungal action of (S)-2-amino-4-oxo-5-hydroxypentanoic acid, RI-331: The inhibition of homoserine dehydrogenase in Saccharomyces cerevisiae. Biochem Biophys Res Commun 1990, 168: 837-43.